A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Institut de Recherches Internationales Servier
With
Breast International Group
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed breast adenocarcinoma.
Presence of an accessible metastatic lesion for biopsy or at least one archived metastatic tumour sample.
Prior first-line systemic therapy in the metastatic setting.
Demonstrated progression of disease by radiological or clinical assessment.
Female patient, aged ≥18 years old.
Estimated life expectancy \>3 months.
Normal Left ventricular function
Adequate haematological, hepatic and renal functions.
For women with childbearing potential, a negative pregnancy test prior to initiation of the study drug and willingness to use an effective contraception.
Ability to swallow oral capsules or tablets.
You may not be if
More than two lines of chemotherapy with or without targeted therapy in the metastatic setting.
Previous treatment with bevacizumab within 3 months of first dose of Investigational Medicinal Product.
Active central nervous system metastases, cerebral oedema, and/or progressive growth.
Patients with impaired cardiac function.
Uncontrolled arterial hypertension
Patients with history of thrombotic disorders or hereditary risk factors of thromboembolic events
Serum potassium level below Lower Limit of Normal
Uncontrolled hypothyroidism.
Pregnant or breastfeeding women.
Clareo Health | A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer
